Circulating Resistin Levels and Risk of Multiple Myeloma in Three Prospective Cohorts

Overview

Journal Br J Cancer

Specialty Oncology

Date 2017 Aug 23

PMID 28829767

Citations 7

Authors

Loredana Santo

Lauren R Teras

Graham G Giles

Stephanie J Weinstein

Demetrius Albanes

Ye Wang

Ruth M Pfeiffer

Qing Lan

Nathaniel Rothman

Brenda M Birmann

Graham A Colditz

Michael N Pollak

Mark P Purdue

Jonathan N Hofmann

Affiliations

Soon will be listed here.

Abstract

Background: Resistin is a polypeptide hormone secreted by adipose tissue. A prior hospital-based case-control study reported serum resistin levels to be inversely associated with risk of multiple myeloma (MM). To date, this association has not been investigated prospectively.

Methods: We measured resistin concentrations for pre-diagnosis peripheral blood samples from 178 MM cases and 358 individually matched controls from three cohorts participating in the MM cohort consortium.

Results: In overall analyses, higher resistin levels were weakly associated with reduced MM risk. For men, we observed a statistically significant inverse association between resistin levels and MM (odds ratio, 0.44; 95% confidence interval (CI) 0.24-0.83 and 0.54; 95% CI 0.29-0.99, for the third and fourth quartiles, respectively, vs the lowest quartile; P=0.03). No association was observed for women.

Conclusions: This study provides the first prospective evidence that low circulating resistin levels may be associated with an increased risk of MM, particularly for men.

Citing Articles

Effect of adipose tissue on the development of multiple myeloma.

Stanislawowski M Mol Biol Rep. 2024; 52(1):74.

PMID: 39708277 DOI: 10.1007/s11033-024-10174-8.

Association of lipid levels, adipokines and multiple myeloma: a two-sample multivariate Mendelian randomization study.

Ding Y, Zhang Y, Zhang X, Shang M, Dong F Sci Rep. 2024; 14(1):25961.

PMID: 39472615 PMC: 11522568. DOI: 10.1038/s41598-024-74838-y.

Obesity as a risk factor for multiple myeloma: insight on the role of adipokines.

Tie W, Ma T, Yi Z, Liu J, Li Y, Bai J Pathol Oncol Res. 2023; 29:1611338.

PMID: 37637774 PMC: 10447903. DOI: 10.3389/pore.2023.1611338.

It is worth the weight: obesity and the transition from monoclonal gammopathy of undetermined significance to multiple myeloma.

Choa R, Panaroni C, Bhatia R, Raje N Blood Adv. 2023; 7(18):5510-5523.

PMID: 37493975 PMC: 10515310. DOI: 10.1182/bloodadvances.2023010822.

Importance of circulating adipocytokines in multiple myeloma: a systematic review and meta-analysis based on case-control studies.

Liu R, Gao D, Lv Y, Zhai M, He A BMC Endocr Disord. 2022; 22(1):29.

PMID: 35073877 PMC: 8787905. DOI: 10.1186/s12902-022-00939-2.

References

Hofmann J, Birmann B, Teras L, Pfeiffer R, Wang Y, Albanes D . Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals. Cancer Res. 2016; 76(7):1935-41. PMC: 4878138. DOI: 10.1158/0008-5472.CAN-15-2406. View

Lee S, Lee H, Kwon Y, Lee S, Cho Y, Kim J . Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes. Cell Metab. 2014; 19(3):484-97. PMC: 3969988. DOI: 10.1016/j.cmet.2014.01.013. View

Thommesen L, Stunes A, Monjo M, Grosvik K, Tamburstuen M, Kjobli E . Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem. 2006; 99(3):824-34. DOI: 10.1002/jcb.20915. View

Schinasi L, Brown E, Camp N, Wang S, Hofmann J, Chiu B . Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium. Br J Haematol. 2016; 175(1):87-101. PMC: 5035512. DOI: 10.1111/bjh.14199. View

Calle E, Rodriguez C, Jacobs E, Almon M, Chao A, McCullough M . The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer. 2002; 94(9):2490-501. DOI: 10.1002/cncr.101970. View

Hofmann J, Liao L, Pollak M, Wang Y, Pfeiffer R, Baris D . A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood. 2012; 120(22):4418-20. PMC: 3507148. DOI: 10.1182/blood-2012-06-438606. View

Giles G, English D . The Melbourne Collaborative Cohort Study. IARC Sci Publ. 2002; 156:69-70. View

Patel L, Buckels A, Kinghorn I, Murdock P, Holbrook J, Plumpton C . Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun. 2002; 300(2):472-6. DOI: 10.1016/s0006-291x(02)02841-3. View

Tilg H, Moschen A . Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006; 6(10):772-83. DOI: 10.1038/nri1937. View

10.

Yannakoulia M, Yiannakouris N, Bluher S, Matalas A, Klimis-Zacas D, Mantzoros C . Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab. 2003; 88(4):1730-6. DOI: 10.1210/jc.2002-021604. View

11.

. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Ann Epidemiol. 1994; 4(1):1-10. DOI: 10.1016/1047-2797(94)90036-1. View

12.

Teras L, DeSantis C, Cerhan J, Morton L, Jemal A, Flowers C . 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016; 66(6):443-459. DOI: 10.3322/caac.21357. View

13.

Rajala M, Lin Y, Ranalletta M, Yang X, Qian H, Gingerich R . Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-alpha in adipose tissue. Mol Endocrinol. 2002; 16(8):1920-30. DOI: 10.1210/me.2002-0048. View

14.

Reseland J, Reppe S, Olstad O, Hjorth-Hansen H, Brenne A, Syversen U . Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma. Eur J Haematol. 2009; 83(5):460-70. DOI: 10.1111/j.1600-0609.2009.01311.x. View

15.

Birmann B, Neuhouser M, Rosner B, Albanes D, Buring J, Giles G . Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood. 2012; 120(25):4929-37. PMC: 3525019. DOI: 10.1182/blood-2012-03-417253. View

16.

Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson K . The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001; 20(33):4519-27. DOI: 10.1038/sj.onc.1204623. View

17.

Dalamaga M, Karmaniolas K, Panagiotou A, Hsi A, Chamberland J, Dimas C . Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study. Cancer Causes Control. 2008; 20(2):193-9. DOI: 10.1007/s10552-008-9233-7. View

18.

Dalamaga M, Sotiropoulos G, Karmaniolas K, Pelekanos N, Papadavid E, Lekka A . Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. Clin Biochem. 2013; 46(7-8):584-90. DOI: 10.1016/j.clinbiochem.2013.01.001. View

19.

Lee J, Chan J, Yiannakouris N, Kontogianni M, Estrada E, Seip R . Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab. 2003; 88(10):4848-56. DOI: 10.1210/jc.2003-030519. View

20.

Curat C, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R . Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006; 49(4):744-7. DOI: 10.1007/s00125-006-0173-z. View